[1]
|
Ramos-Casals, M., Brahmer, J.R., Callahan, M.K., et al. (2020) Immune-Related Adverse Events of Checkpoint Inhibi-tors. Nature Reviews Disease Primers, 6, Article No. 38. https://doi.org/10.1038/s41572-020-0160-6
|
[2]
|
Bhardwaj, M., Chiu, M.N. and Pilkhwal, S.A.H.S. (2022) Ad-verse Cutaneous Toxicities by PD-1/PD-L1 Immune Checkpoint Inhibitors: Pathogenesis, Treatment, and Surveillance. Cutaneous and Ocular Toxicology, 41, 73-90.
https://doi.org/10.1080/15569527.2022.2034842
|
[3]
|
Xia, C., Dong, X., Li, H., et al. (2022) Cancer Statistics in China and United States, 2022: Profiles, Trends, and Determinants. Chinese Medical Journal (England), 135, 584-590. https://doi.org/10.1097/CM9.0000000000002108
|
[4]
|
Baxi, S., Yang, A., Gennarelli, R.L., et al. (2018) Im-mune-Related Adverse Events for Anti-PD-1 and Anti-PD-L1 Drugs: Systematic Review and Meta-Analysis. BMJ, 360, k793. https://doi.org/10.1136/bmj.k793
|
[5]
|
Dodiuk-Gad, R.P., Chung, W.H., Valeyrie-Allanore, L., et al. (2015) Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. American Journal of Clinical Dermatology, 16, 475-493.
https://doi.org/10.1007/s40257-015-0158-0
|
[6]
|
Riano, I., Cristancho, C. and Treadwell, T. (2020) Ste-vens-Johnson Syndrome-Like Reaction after Exposure to Pembrolizumab and Recombinant Zoster Vaccine in a Patient with Metastatic Lung Cancer. Journal of Investigative Medicine High Impact Case Reports, 8. https://doi.org/10.1177/2324709620914796
|
[7]
|
Fessas, P., Possamai, L.A., Clark, J., et al. (2020) Immunotoxici-ty from Checkpoint Inhibitor Therapy: Clinical Features and Underlying Mechanisms. Immunology, 159, 167-177. https://doi.org/10.1111/imm.13141
|
[8]
|
Lu, J., Thuraisingam, T., Chergui, M., et al. (2019) Nivolumab-Associated DRESS Syndrome: A Case Report. JAAD Case Reports, 5, 216-218. https://doi.org/10.1016/j.jdcr.2018.11.017
|
[9]
|
姚雄宇, 董秀哲, 侯国军, 等. 替雷利珠单抗免疫相关性Stevens-Johnson综合征1例[J]. 中国医院药学杂志, 2023, 43(2): 237-238.
|
[10]
|
Storandt, M.H. and Seth, R. (2021) A Case of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient Receiving Chemo-Immunotherapy with Pemetrexed and Pembrolizumab. Current Problems in Cancer: Case Reports, 3, Article ID: 100048. https://doi.org/10.1016/j.cpccr.2020.100048
|
[11]
|
Saw, S., Lee, H.Y. and Ng, Q.S. (2017) Pembrolizumab-Induced Stevens-Johnson Syndrome in Non-Melanoma Patients. European Jour-nal of Cancer, 81, 237-239. https://doi.org/10.1016/j.ejca.2017.03.026
|
[12]
|
Dasanu, C.A. (2019) Late-Onset Ste-vens-Johnson Syndrome Due to Nivolumab Use for Hepatocellular Carcinoma. Journal of Oncology Pharmacy Practice, 25, 2052-2055. https://doi.org/10.1177/1078155219830166
|
[13]
|
Gracia-Cazaña, T., Padgett, E., Calderero, V., et al. (2021) Nivolumab-Associated Stevens-Johnson Syndrome in a Patient with Lung Cancer. Dermatology Online Journal, 27, Article No. 13. https://doi.org/10.5070/D3273052777
|
[14]
|
Adverse Drug Reaction Research Center of Chinese Society of Dermatology (2021) Expert Consensus on the Diagnosis and Treatment of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Chinese Journal of Dermatology, 54, 376-381.
|
[15]
|
Zhang, S., Tang, S., Li, S., et al. (2020) Bi-ologic TNF-alpha Inhibitors in the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Sys-temic Review. Journal of Dermatological Treatment, 31, 66-73.
https://doi.org/10.1080/09546634.2019.1577548
|
[16]
|
Morita, K., Matsui, H., Michihata, N., et al. (2019) Associa-tion of Early Systemic Corticosteroid Therapy with Mortality in Patients with Stevens-Johnson Syndrome or Toxic Epi-dermal Necrolysis: A Retrospective Cohort Study Using a Nationwide Claims Database. American Journal of Clinical Dermatology, 20, 579-592.
https://doi.org/10.1007/s40257-019-00443-9
|
[17]
|
Kridin, K., Bruggen, M.C., Chua, S.L., et al. (2021) Assessment of Treatment Approaches and Outcomes in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Insights from a Pan-European Multicenter Study. JAMA Dermatology, 157, 1182-1190. https://doi.org/10.1001/jamadermatol.2021.3154
|